Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Large Decline in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totaling 94,135 shares, a decrease of 36.2% from the April 30th total of 147,543 shares. Based on an average daily volume of 35,197 shares, the days-to-cover ratio is presently 2.7 days. Currently, 0.5% of the shares of the company are short sold.

Estrella Immunopharma Stock Performance

NASDAQ:ESLA opened at $1.07 on Thursday. The stock has a fifty day moving average price of $1.35 and a two-hundred day moving average price of $1.37. The stock has a market capitalization of $45.83 million, a price-to-earnings ratio of -3.13 and a beta of 0.85. Estrella Immunopharma has a 1 year low of $0.78 and a 1 year high of $3.15.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. On average, analysts predict that Estrella Immunopharma will post -0.39 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ESLA. Quadrature Capital Ltd acquired a new stake in Estrella Immunopharma in the fourth quarter valued at $43,000. State Street Corp grew its holdings in Estrella Immunopharma by 93.5% in the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after purchasing an additional 20,900 shares during the last quarter. XTX Topco Ltd grew its holdings in Estrella Immunopharma by 376.9% in the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after purchasing an additional 39,099 shares during the last quarter. Marshall Wace LLP acquired a new stake in Estrella Immunopharma in the fourth quarter valued at $88,000. Finally, Geode Capital Management LLC grew its holdings in Estrella Immunopharma by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after purchasing an additional 8,318 shares during the last quarter. Hedge funds and other institutional investors own 0.35% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ESLA shares. D. Boral Capital restated a “buy” rating and set a $8.00 price target on shares of Estrella Immunopharma in a research note on Monday, February 9th. Weiss Ratings cut Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.00.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.